Generate Biomedicines, Inc. (GENB) Stock Forecast
GENB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $27.00 average of analyst targets
- Upside to target
- +123.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.50
- 52-week range
- $11.21 – $20.38
GENB analyst ratings
6 analystsNumber of analysts at each rating.
GENB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GENB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.55 | −$0.67 | −$0.44 | — | — | 4 |
| Current fiscal year (2026) | −$2.30 | −$2.50 | −$2.14 | — | — | 4 |
| Next fiscal year (2027) | −$2.28 | −$2.72 | −$1.53 | −$2.30 | +0.9% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GENB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.8M | $5.0M | $10.0M | — | 5 |
| Current fiscal year (2026) | $29.7M | $23.5M | $38.5M | — | 6 |
| Next fiscal year (2027) | $23.8M | $0 | $40.0M | −19.7% | 6 |
GENB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GENB revenue: reported and forecast
GENB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.58 | −$0.55 | −$0.55 | −$0.55 | +0.9% | 1 up · 2 down |
| Current fiscal year (2026) | −$2.24 | −$2.35 | −$2.30 | −$2.30 | −$2.30 | +2.7% | 2 up · 2 down |
| Next fiscal year (2027) | −$2.06 | −$2.28 | −$2.28 | −$2.28 | −$2.28 | +10.4% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GENB earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; GENB beat in 0 of 2.
What analysts expect from GENB
6 analysts cover Generate Biomedicines; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $27.00, 123.3% above the latest close of $12.09. Analysts expect earnings of −$2.30 per share for 2026. For 2027 the average estimate is −$2.28 per share on revenue of $23.8 million. Generate Biomedicines beat the EPS estimate in 0 of the last 2 quarters.
Related: GENB income statement, GENB key metrics, GENB chart. See the GENB stock overview for the latest quote and news.
GENB forecast FAQ
What is Generate Biomedicines's price target?
The average analyst price target for Generate Biomedicines is $27.00, 123.3% above the latest close of $12.09.
Is Generate Biomedicines a buy, hold or sell?
Of 6 analysts covering Generate Biomedicines, 4 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Generate Biomedicines's EPS forecast?
Analysts forecast −$2.30 per share for 2026 (range −$2.50 to −$2.14); for 2027 the estimate is −$2.28.
What is Generate Biomedicines's revenue forecast?
The average revenue estimate for 2026 is $29.7 million; for 2027 it is $23.8 million.
When does Generate Biomedicines report earnings?
Generate Biomedicines is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.50.
Does Generate Biomedicines usually beat earnings estimates?
Generate Biomedicines reported EPS at or above the analyst estimate in 0 of the last 2 quarters.